The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• The ETS-related gene (ERG) transcription factor is implicated in various cancers, notably leukemia.
• Understanding the specific ERG domains and co-factors driving leukemogenesis is essential for therapeutic development.
• Targeting transcription factors like ERG presents significant challenges in drug discovery.

Purpose of the Study:

• To identify critical ERG domains and interactions involved in inducing leukemia.
• To investigate the role of a specific proline residue (P199) in ERG's oncogenic function.
• To explore the potential of targeting the ERG-NCoR-HDAC3 complex as a therapeutic strategy.

Main Methods:

• Site-directed mutagenesis to alter the proline at position 199 (P199) in the ERG PNT domain.
• Assays to evaluate ERG's effects on hematopoietic progenitor cell self-renewal and differentiation.
• Leukemia induction studies in mouse models.
• Co-immunoprecipitation to assess ERG's interaction with the NCoR-HDAC3 complex.
• Inhibition studies using HDAC3 inhibitors in cancer cell lines.

Main Results:

• A conserved proline at position 199 (P199) within the ERG PNT domain is essential for ERG-induced leukemia.
• P199 is required for ERG to enhance self-renewal and block myeloid differentiation in hematopoietic progenitor cells.
• P199 mediates the interaction between ERG and the NCoR-HDAC3 co-repressor complex.
• Inhibition of HDAC3 activity significantly reduces the proliferation of ERG-driven leukemia and prostate cancer cells.

Conclusions:

• The P199 residue in ERG plays a critical role in its leukemogenic activity by facilitating interaction with the NCoR-HDAC3 complex.
• The ERG-NCoR-HDAC3 interaction is vital for ERG's oncogenic functions.
• Targeting the interaction between ERG and the NCoR-HDAC3 co-repressor complex represents a promising therapeutic avenue for ERG-dependent cancers.